India is one of the leading pharmaceutical manufacturing and export hubs across the world. The country supplies high-quality medicines to more than 200 countries worldwide. According to industry estimates, India makes a total contribution to generic medicines of nearly 20% by volume and is among the largest exporters of vaccines, oncology medicines, and specialty pharmaceutical products.
As a trusted pharmaceutical exporter from India, Ikris Pharma Network supports global pharmaceutical importers, distributors, hospitals, NGOs, and healthcare procurement companies with reliable access to specialty medicines, biologics, oncology products, and immunotherapy treatments.
With increasing healthcare demand in countries like LATAM, Africa, Central America, and Caribbean markets, pharmaceutical importers source medicines from India for the following reasons:
Competitive pricing
Strong manufacturing capabilities
WHO-GMP and global regulatory standards
Availability of specialty medicines
Expanding biologics and oncology portfolios
Pharmaceutical Export from India to Global Markets:
Ikris Pharma Network supports pharmaceutical exports from India to multiple international markets, including:
All these regions are witnessing high demand for oncology medicines, biologics, immunotherapy products, and specialty pharmaceutical treatments.
Why Global Demand for Indian Pharmaceutical Exports is Increasing:
The global pharmaceutical market is evolving exponentially, especially in oncology, autoimmune diseases, rare diseases, and biologics.
Rising Cancer Burden Worldwide: According to global healthcare estimates, cancer cases are projected to exceed 30 million annually by 2040, creating higher demand for:
Immunotherapy medicines
Monoclonal antibodies
Targeted oncology therapies
Chemotherapy medicines
Countries across Africa and LATAM often depend heavily on imported oncology and specialty medicines because local manufacturing capacity remains limited.
Growing Demand for Affordable Biologics: The global biologics market is expected to surpass USD 700 billion in the coming years, while many specialty therapies remain costly in developing regions. Pharmaceutical exporters from India help improve treatment accessibility through cost-effective sourcing solutions.
Biologic medicines such as:
Adalimumab
Ustekinumab
Vedolizumab
Rituximab
Omalizumab
continue to see growing demand globally.
Expansion of Healthcare Infrastructure: Healthcare spending across emerging markets continues to rise steadily, increasing demand for:
Hospital oncology procurement
Specialty medicine imports
Immunotherapy products
Rare disease treatments
Cold-chain biologic medicines
As a result, pharmaceutical exporters from India are becoming critical supply partners for hospitals, distributors, and healthcare organizations worldwide.
List of Medicines Available for Export from India Through Ikris Pharma Network:
Ikris Pharma Network supplies a wide portfolio of oncology medicines, biologics, specialty drugs, immunotherapy products, and critical care medicines for international pharmaceutical procurement.
Oncology & Hematology Medicines:
Nivolumab
Trastuzumab emtansine
Trastuzumab
Pertuzumab
Bevacizumab
Rituximab
Cetuximab
Daratumumab
Tislelizumab
Abemaciclib
Nelarabine
Fludarabine Phosphate
Cisplatin
Carboplatin
Paclitaxel
Oxaliplatin
Cabozantinib
Topotecan
Trabectedin
Tucatinib
Crizotinib
Olaparib
Mitotane
Toripalimab
These medicines are widely used in the treatment of Breast cancer, Lung cancer, Leukemia, Lymphoma, Colorectal cancer, Ovarian cancer, Gastric cancer, Liver cancer, and Advanced solid tumors.
Biologics & Immunotherapy Medicines:
Ustekinumab
Adalimumab
Infliximab
Omalizumab
Itolizumab
Vedolizumab
Denosumab
Nimotuzumab
These biologic therapies are commonly used in Autoimmune diseases, Gastroenterology, Respiratory medicine, Immunology, Inflammatory bowel disease, and Targeted cancer therapy.
These specialty medicines are increasingly important in Diabetes management, Rare metabolic disorders, Autoimmune diseases, and Chronic inflammatory conditions.
Anti-Infective & Critical Care Medicines:
Amphotericin B
Dalbavancin
These medicines are widely used in hospitals and critical care environments for treating serious fungal and bacterial infections.
Challenges Global Importers Face When Sourcing Specialty Medicines:
International pharmaceutical procurement involves several operational and regulatory challenges.
Cold Chain Management: Many oncology and biologic medicines require strict temperature-controlled shipping conditions throughout international transit.
Regulatory Documentation Complexity: Different countries require different import documentation, making pharmaceutical exports highly compliance-driven.
Product Availability Fluctuations: Global shortages and increasing demand can impact medicine availability and procurement timelines.
Counterfeit Medicine Risks: Healthcare buyers increasingly prioritize sourcing from trusted pharmaceutical exporters from India with reliable supply networks and traceability support.
How Ikris Pharma Network Supports International Pharmaceutical Procurement
As a pharmaceutical exporter from India, Ikris Pharma Network supports global healthcare buyers with:
Regulatory Coordination: Support for export-related documentation and international pharmaceutical compliance processes.
GDP-Compliant Logistics: Temperature-controlled shipping coordination for biologics, oncology products, and specialty medicines.
Global Supply Network: Access to a broad portfolio of specialty medicines through established sourcing channels and manufacturing networks.
Batch Traceability Support: Coordination for traceability and authentication requirements for international pharmaceutical supply.
Specialized Packaging Solutions: Cold-chain and secure packaging support for temperature-sensitive medicines.
Why India is a Preferred Source for Specialty Medicines:
India has become one of the most important global pharmaceutical supply centers because of:
Large-scale manufacturing infrastructure
Cost-effective medicine production
WHO-GMP compliant facilities
Availability of generic oncology medicines
Growing biologics manufacturing capabilities
International regulatory approvals
Many Indian pharmaceutical manufacturers are approved by:
With increasing global demand for specialty medicines, biologics, oncology products, and immunotherapy treatments, pharmaceutical exporters from India continue to play a vital role in improving healthcare accessibility worldwide.
Ikris Pharma Network supports pharmaceutical buyers across LATAM, Africa, Central America, and Caribbean markets with access to:
By combining global sourcing capabilities, regulatory coordination, and pharmaceutical export expertise, we help international healthcare organizations access high-quality medicines from India efficiently and reliably.
Frequently Asked Questions (FAQs):
What medicines are available for export from India?
India exports a wide range of medicines, including oncology drugs, biologics, immunotherapy medicines, specialty treatments, rare disease medicines, and critical care pharmaceuticals.
Who is a trusted pharmaceutical exporter from India?
Ikris Pharma Network is a pharmaceutical exporter from India supporting global buyers with oncology medicines, biologics, specialty drugs, and international pharmaceutical export solutions.
Which oncology medicines are commonly exported from India?
Common oncology medicines exported from India include Nivolumab, Trastuzumab, Rituximab, Bevacizumab, Olaparib, Paclitaxel, Cisplatin, and Cabozantinib.
Can biologic medicines be exported from India to Africa and LATAM?
Yes, biologic medicines such as Adalimumab, Ustekinumab, Vedolizumab, Denosumab, and Omalizumab are exported from India to multiple global markets, subject to local import regulations.
Why do importers source specialty medicines from India?
Importers source medicines from India because of competitive pricing, strong manufacturing capabilities, broad medicine availability, and international regulatory compliance standards.
What challenges exist in importing oncology and biologic medicines?
Common challenges include cold-chain management, regulatory documentation, customs clearance, medicine shortages, and counterfeit medicine risks.
Does Ikris Pharma Network support temperature-sensitive pharmaceutical exports?
Yes, Ikris Pharma Network supports GDP-compliant logistics coordination and cold-chain handling for temperature-sensitive biologics and oncology medicines.